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The value of endoscopic Barrett esophagus (BE) surveillance based on histological diagnosis of low-grade dysplasia (LGD) remains
debated given the lack of adequate risk stratiﬁcation. The aim of this study was to evaluate the predictive value of cyclin A expression
and to combine these results with our previously reported immunohistochemical p53, AMACR, and SOX2 data, to identify a panel of
biomarkers predicting neoplastic progression in BE.
We conducted a case–control study within a prospective cohort of 720 BE patients. BE patients who progressed to high-grade
dysplasia (HGD, n=37) or esophageal adenocarcinoma (EAC, n=13), deﬁned as neoplastic progression, were classiﬁed as cases
and patients without neoplastic progression were classiﬁed as controls (n=575). Cyclin A expression was determined by
immunohistochemistry in all 625 patients; these results were combined with the histological diagnosis and our previous p53,
AMACR, and SOX2 data in loglinear regression models. Differences in discriminatory ability were quantiﬁed as changes in area under
the ROC curve (AUC) for predicting neoplastic progression.
Cyclin A surface positivity signiﬁcantly increased throughout the metaplasia–dysplasia–carcinoma sequences and was seen in 10%
(107/1050) of biopsy series without dysplasia, 33% (109/335) in LGD, and 69% (34/50) in HGD/EAC. Positive cyclin A expression was
associated with an increased risk of neoplastic progression (adjusted relative risk (RRa) 2.4; 95% CI: 1.7–3.4). Increases in AUC were
substantial for P53 (+0.05), smaller for SOX2 (+0.014), minor for cyclin A (+0.003), and none for AMARC (0.00).
Cyclin A immunopositivity was associated with an increased progression risk in BE patients. However, compared to p53 and SOX2,
the incremental value of cyclin A was limited. The use of biomarkers has the potential to signiﬁcantly improve risk stratiﬁcation in BE.
Abbreviations: ACG = American College of Gastroenterology, AUC = area under the curve, BE = Barrett esophagus, CI =
conﬁdence interval, DAB = diaminobenzidine, EAC = esophageal adenocarcinoma, FFPE = formalin-ﬁxed parafﬁn-embedded, HGD
= high-grade dysplasia, HRP-ABC = horseradish peroxidase avidin–biotin complex, IQR = interquartile range, LGD = low-grade
dysplasia, NDBE = nondysplastic BE, NPV = negative predictive value, PPV = positive predictive value, ROC = receiver operating
characteristic, RR = relative risk.
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Barrett esophagus (BE) is a premalignant condition of the distal
dures were performed according to a standardized protocol, byesophagus in which the normal squamous epithelium is replaced
by columnar epithelium containing goblet cells, as a result of
chronic acid exposure.[1–3] Patients with BE have an increased
risk to develop esophageal adenocarcinoma (EAC) with an
estimated incidence of 0.2% to 0.5% per year.[4–7] The transition
from BE to EAC is a gradual process, in which intestinal
metaplasia evolves via low-grade dysplasia (LGD), to high-grade
dysplasia (HGD) and ﬁnally to EAC, a cancer with an overall 5-
year survival of less than 20%.[8,9] Current guidelines recom-
mend endoscopic surveillance of BE patients to detect HGD or
EAC at an early and potentially curable stage when endoscopic
treatment is still feasible.[10,11] However, the applied endoscopic
surveillance strategy to date based on histological diagnosis alone
remains debated given the overall low incidence of neoplastic
progression, and the lack of discriminative power to stratify
BE patients at high risk for neoplastic progression from those at
low risk.
Histological diagnosis of LGD is nowadays used for the risk
assessment of neoplastic progression in BE surveillance and more
intensive follow-up is recommended in LGD patients (yearly
instead of every 3 years).[10–12] However, diagnosis of LGD has a
low predictive value, owing to sample error and a considerable
inter- and intraobserver variation.[13–15] The use of (a panel of)
biomarkers in addition to histology may improve risk stratiﬁca-
tion in BE patients, and several immunohistochemical biomark-
ers are under investigation. Our group previously reported on the
predictive value for neoplastic progression of p53, AMACR, and
SOX2 in a large prospective cohort of patients with BE.[16–18]
Another potential biomarker is cyclin A, a protein that plays an
important role in the G1-S transition of the cell cycle.
Overexpression of cell-cycle related proteins, including cyclin
A, has been linked to the metaplasia–dysplasia–carcinoma
sequence in BE and associated with an increased risk of
neoplastic progression.[19–21] However, clinical validation of
cyclin A in a large prospective cohort of BE patients is still
missing. In addition, there is a lack of studies testing performance
of multiple biomarker simultaneously in the same cohort of BE
patients.
The aim of the present study was to assess the value of cyclin A
immunohistochemistry to predict neoplastic progression in a
large cohort of BE patients and to combine the results obtained
with our previously reported p53, AMACR, and SOX2
immunohistochemical data in the same prospective cohort, to
identify a panel of biomarkers predictive for neoplastic
progression in patients with BE.2. Methods
2.1. Study design
We conducted a case–control study nested within a large
multicenter prospective cohort of 720 BE patients. All patients
were included between November 2003 and December 2004
from 3 university medical centers and 12 regional hospitals
throughout the Netherlands and received endoscopic surveillance
according to the guidelines of the American College of
Gastroenterology (ACG) (Appendix 1, http://links.lww.com/
MD/B406).[11] Inclusion criterion was known or newly diag-
nosed BE of at least 2cm according to the Prague C&M criteria,
histologically conﬁrmed by the presence of intestinal metaplasia
on initial biopsies.[22] Patients with a history of HGD or2esophageal malignancy were excluded. All endoscopic proce-
an experienced gastroenterologist with at least several years of
experience in endoscopic procedures and with interest for BE.
Before taking biopsies, endoscopic landmarks such as the
diaphragm impression, gastroesophageal junction, and squamo-
columnar junction were reported. The presence of esophagitis
was graded according to the Los Angeles Classiﬁcation, and
abnormalities were noted, including nodules, ulcers, and
erosions.[23] At each endoscopic procedure targeted biopsies
were taken from mucosal abnormalities and quadrant biopsies
were taken every 2cm from the most distal to the most proximal
part of the Barrett segment, according to the Seattle protocol.[24]
Patients without dysplasia in the biopsy samples, based on
histological consensus diagnosis, underwent endoscopy surveil-
lance with biopsy sampling every 3 years and patients with LGD
every year.2.2. Histology
According to standard procedure, all biopsy samples were ﬁxated
with buffered formalin and embedded in parafﬁn. From each
biopsy set, 4-mm thick sections were cut and stained with
hematoxylin–eosin to assess the presence of BE and grade of
dysplasia. After assessment of all the biopsies, the highest degree
of abnormality was reported for each endoscopy. Slides were
graded ﬁrst by a local pathologist and secondly by an expert
academic pathologist. In case of disagreement on the grade of
dysplasia between the local pathologist and expert academic
pathologist, the slides were reviewed by a second expert academic
pathologist. Pathologists were blinded for each other’s diagnosis
and a ﬁnal diagnosis was made if at least 2 pathologists agreed on
the grade of dysplasia. When there was still disagreement, a panel
of expert pathologists reviewed the slides and a ﬁnal diagnosis
was made based on consensus agreement. Given the equal
surveillance strategy according to the ACG guidelines, the
biopsies (n=7) with the ﬁnal diagnosis of indeﬁnite for dysplasia
were included in the group of biopsies with the diagnosis of LGD.2.3. Patient selection
We collected formalin-ﬁxed parafﬁn-embedded (FFPE) material
suitable for immunohistochemistry from all 720 BE patients in
our cohort. However, no material or not enough material was
available in 95 patients, leaving 625 patients to be included in this
analysis. Patients with progression to HGD or EAC during
follow-up were classiﬁed as cases and patients without neoplastic
progression were classiﬁed as controls. In accordance with our
previous analyses, the minimal time interval between the index
endoscopy and diagnosis of HGD or EAC was 9 months to
prevent inclusion of prevalent cases. Immunohistochemistry
was performed on the complete series of FFPE material of all
surveillance endoscopies of patients who developed any form of
dysplasia, that is, LGD, HGD, or EAC during follow-up. This
included the total number of biopsies taken during surveillance at
different levels of the Barrett segment. In patients without any
form of dysplasia during follow-up, immunohistochemistry was
performed on biopsies of a random surveillance endoscopy.2.4. Immunohistochemistry
For cyclin A immunohistochemistry, FFPE tissue sections were
deparafﬁnized in xylene and rehydrated in graded alcohols.
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endogenous peroxidase activity was blocked by incubating the
slides in a solution of 0.3% hydrogen peroxide in phosphate-
buffered saline. Primary antibody (Leica, Novocastra, Newcastle
upon Tyne, United Kingdom: monoclonal, mouse) with a
dilution of 1:200 was incubated overnight at 4°C. Rabbit
antimouse (1:150; E0413, Dako, Heverlee, Belgium) was used as
secondary antibody. Visualization was achieved by using the
horseradish peroxidase avidin–biotin complex (HRP-ABC)
method and diaminobenzidine (DAB) substrate. Finally, slides
were counterstained with hematoxylin. A negative control was
obtained by omission of the primary antibody. Positive nuclei in
the proliferation zone of the BE epithelium were used as internal
positive control. Immunohistochemical staining for p53,
AMACR, and SOX2 was performed as previously
described.[16–18]2.5. Scoring of immunohistochemistry
Immunohistochemically stained slides were examined in tandem
with the hematoxylin–eosin stained slides to determine cyclin A,
and previously p53, AMACR, and SOX2 expression in areas
with dysplasia.[16–18] Nuclear cyclin A expression was scored on
a 2-point scale; negative or positive expression. The surface cells
were counted up to a maximum of 600 cells to determine the
percentage of cyclin A positive cells. Only surface cells with
strong nuclear staining were considered as positive. The epithelial
surface was deﬁned as the columnar cells at the luminal side of the
biopsy, as described previously.[25] Based on published data, a
cut-off value of 1% or more was used for cyclin A positivity.[21]
Cyclin A expression was scored in BE epithelium with the highest
percentage of positive cyclin A cells and in biopsy series with
dysplasia, cyclin A expression was scored in the dysplastic area.
After scoring all biopsies, the highest degree of abnormality was
reported for each surveillance endoscopy. All stained slides were
scored by 2 independent expert investigators who were blinded
for long-term outcome as well as each other’s results. When there
was disagreement between the 2 investigators, slides were
reviewed by an experienced academic pathologist (KB or MD)
and ﬁnal diagnosis was made if 2 investigators agreed on the
extend of cyclin A expression.
P53, AMACR, and SOX2 expression was scored as previously
described.[16–18] Brieﬂy, nuclear p53 and cytoplasmatic AMACR
expression were scored on a 3-point scale (p53; normal
expression, overexpression, or loss of expression and for
AMACR; no expression, mild expression, or strong expression).
Only intense nuclear staining for p53 was scored as over-
expression and aberrant p53 expression was deﬁned as either
overexpression or complete loss of expression in at least 1 gland.
Nuclear SOX2 expression was scored on a 2-point scale; positive
or loss of expression. Positive expression included strong as well
as weak nuclear SOX2 positivity and was interpreted as normal
expression. Loss of SOX2 expression in a cluster of glands,
excluding BE glands containing many goblet cells was deﬁned as
aberrant SOX2 expression.2.6. Ethics
The study protocol was approved by the institutional review
board of the Erasmus University Medical Center, including
those of all participating hospitals. Before the ﬁrst endoscopy,
written informed consent was obtained from all 720 BE
patients.32.7. Statistical analysis
Patient characteristics of cases and controls were compared using
Mann–Whitney U test for continuous variables and x2 test for
categorical variables. To compare cyclin A expression in biopsy
series of cases and controls with different grade of dysplasia, the
Mann–WhitneyU test and Kruskal–Wallis test were used, thereby
ignoring thatmultiple biopsy series could be from the same patient.
Neoplastic progressionwas deﬁned as the development ofHGDor
EAC at least 9 months after inclusion in the study, and follow-up
time was deﬁned as the time between 2 consecutive surveillance
endoscopies.ThevalueofcyclinAimmunohistochemistrytopredict
neoplasticprogressionwasestimatedinloglinearregressionmodels.
Previous stained slides for p53, AMACR, and SOX2 expression in
the same cohort of BE patients were reevaluated in this study to
explore the classiﬁcation performance of different combinations of
biomarkers for predicting neoplastic progression in BE. Because
immunohistochemical staining was not performed on all biopsy
series, dataweresplit upbyendoscopy (1243 in575controls, 142 in
50 cases). Loglinear models were used to calculate relative risks
(RRs) and 95% conﬁdence intervals (CIs) with the logarithm of
follow-up time (time between 2 consecutive endoscopies) as offset
variable. In multivariable analysis we adjusted for gender, age, BE
length, and esophagitis to estimate adjusted RRs and 95%CIs. For
eachof thebiomarkers the sensitivity, speciﬁcity, positivepredictive
value (PPV), and negative predictive value (NPV) was calculated.
The areas under the receiver operating characteristic (ROC) curves
for neoplastic progression were calculated for the individual
markers as well as for the comparison between a selection of
models, inwhich the studiedbiomarkerswere includedor excluded.
These included pathological diagnosis of grade of dysplasia alone,
pathological diagnosis in combination with p53 and SOX2
immunohistochemistry and pathological diagnosis in combination
with p53, SOX2, and cyclin A immunohistochemistry. The
incremental value of each biomarker was calculated by the change
in area under the curve (AUC) after exclusion of the concerning
biomarker in the “fully adjusted model” (model including
histological diagnosis, cyclin A, p53, AMACR, and SOX2
immunohistochemistry) as described earlier.[26] Interobserver
agreement for cyclinA expressionwas determined byCohen kappa
statistics. Kappa value of below0.21were considered“poor,” 0.21
to 0.40 “fair,” 0.41 to 0.60 “moderate,” 0.61 to 0.8 “substantial,”
andabove 0.81“very good.”[27] Two-sidedP values of<0.05were
considered statistically signiﬁcant. Data were analyzed using SPSS
statistical software (V.21.0; IBM SPSS, Chicago, IL).3. Results
3.1. Patient characteristics
Six hundred twenty-ﬁve patients with BE were included in this
study (74% men, median age of 60 years (interquartile range
(IQR) 53–69)) and followed for a median duration of 6.7 years
(IQR 5.0–7.4). Thirty-seven (6%) patients developed HGD and
13 (2%) patients developed EAC during surveillance after a
median follow-up of 3.2 years (IQR 1.9–5.3). These 50 (8%) BE
patients with neoplastic progression were classiﬁed as cases and
the remaining 575 (92%) patients without neoplastic progression
were classiﬁed as controls. Cyclin A expression was scored
separately and subsequently correlated with histological diagno-
sis and expression of p53, AMACR, and SOX2 in biopsy series of
1432 endoscopies: 189 endoscopies were performed in 50 cases
and 1243 endoscopies in 575 controls. Biopsy series were deﬁned
as the total number of biopsies from 1 endoscopy and the highest
Table 1
Baseline characteristics of cases and controls.
Controls, n=575 Cases, n=50 P
Follow-up
Median, years (IQR) 6.5 (5.2–7.2) 3.2 (1.9–5.3) <0.001
Endoscopies
Median number (IQR) 4 (4–5) 3 (2–4) <0.001
Biopsies available
Median number per
endoscopy (IQR)
6 (4–9) 9 (6–12) <0.001
Age
Median, years (IQR) 60 (53–69) 65 (56–71) 0.103
Male sex 419 (73%) 41 (82%) 0.160
Alcohol use
Never 66 (12%) 6 (12%) 0.981
Former 52 (9%) 5 (10%)
Current 445 (79%) 39 (78%)
Smoking
Never 189 (34%) 12 (24%) 0.362
Former 256 (45%) 25 (50%)
Current 118 (21%) 13 (26%)
Reﬂux symptoms 172 (30%) 19 (38%) 0.265
Barrett diagnosis
1999 231 (41%) 16 (32%) 0.473
2000–2002 197 (34%) 19 (38%)
2003–2004 141 (25%) 15 (30%)
Barrett length
Median, cm (IQR) 4 (3–6) 5 (4–7) 0.010
Low-grade dysplasia at baseline 88 (15%) 24 (48%) <0.001
Esophagitis 109 (19%) 14 (30%) 0.104
IQR= interquartile range.
Patients with neoplastic progression were classiﬁed as cases and patients without neoplastic
progression were classiﬁed as controls.
Mann–Whitney U test and Chi-square test were used to compare the characteristics of cases and
controls.
Figure 1. Receiver operating characteristic (ROC) comparing different
biomarker models with the basic pathological diagnosis of grade of dysplasia.
Area under the curve (AUC) for predicting neoplastic progression was
calculated (pathological diagnosis grade of dysplasia AUC of 0.62 (95% CI:
0.58–0.68), pathological diagnosis+p53 and SOX2 immunohistochemistry
AUC of 0.72 (95%CI: 0.67–0.77) and pathological diagnosis+p53, SOX2, and
cyclin A immunohistochemistry AUC of 0.72 (95% CI: 0.67–0.77)).
van Olphen et al. Medicine (2016) 95:47 Medicinedegree of abnormality was reported for each surveillance
endoscopy after evaluation of all biopsies taken at that respective
endoscopyprocedure. Except for a smaller number of endoscopies,
a higher number of biopsies per endoscopy, longer BE length and
more frequent diagnosis of LGD at baseline there were no
signiﬁcant differences between the cases and controls (Table 1).
3.2. Histology
Consensus histology assessments included, 1050 (73%) biopsy
series with nondysplastic BE (NDBE), 335 (23%) with LGD, 34Table 2
Histology and cyclin A immunohistochemistry in biopsy series of cas
Variable Controls, n=1243
Histology
ND 975 (78%)
LGD 268 (22%)
Cyclin A expression
<1% 1073 (86%)
≥1% 170 (14%)
Histology and cyclin A expression
ND and <1% cyclin A positivity 883 (71%)
LGD and <1% cyclin A positivity 190 (15%)
ND and ≥1% cyclin A positivity 92 (8%)
LGD and ≥1% cyclin A positivity 78 (6%)
The highest degree of abnormality was reported for each endoscopy after examining all biopsies.
BE=Barrett esophagus, CI= conﬁdence interval, LGD= low-grade dysplasia, ND=no dysplasia, RR= r
∗
RR adjusted for gender, age, BE length, and esophagitis.
4(3%)withHGD, and13 (1%)withEAC.The local pathologist and
expert academic pathologist disagreed ongrade of dysplasia in 421
(29%) biopsy series and these samples were reviewed by a second
expert pathologist (kappa-value of 0.34; 95% CI: 0.32–0.36). In
22 (19%) biopsy series there was still disagreement and a second
expert pathologist or a panel of expert pathologists reviewed the
slides for aﬁnal diagnosis. The presence ofLGDwasmore frequent
in biopsy series of cases (47%) than in biopsy series of controls
(22%) and was associated with an increased risk of neoplastic
progression after adjusting for gender, age, BE length, and
esophagitis (adjustedRRof 3.9; 95%CI: 2.8–5.4), with anAUCof
0.62 (95% CI: 0.58–0.68) (Table 2 and Fig. 1). The sensitivity of
histological diagnosisofLGDfor predictingneoplasticprogressiones and controls.
Cases, n=142 RR (95% CI) RR
∗
(95% CI)
75 (53%) Reference Reference
67 (47%) 4.2 (3.0–5.8) 3.9 (2.8–5.4)
96 (68%) Reference Reference
46 (32%) 2.7 (1.9–3.8) 2.4 (1.7–3.4)
60 (42%) Reference Reference
36 (25%) 3.8 (2.5–5.8) 3.5 (2.3–5.3)
15 (11%) 2.0 (1.2–3.6) 1.7 (0.9–3.0)
31 (22%) 6.4 (4.1–9.9) 5.8 (3.7–9.0)
elative risk as calculated from a log-linear regression model.
Table 3
Performance of each individual marker for predicting neoplastic progression.
Biomarker Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) AUC (95% CI)
Low-grade dysplasia 47 78 20 93 0.62 (0.58–0.68)
Cyclin A positivity 32 86 21 92 0.59 (0.54–0.64)
Aberrant p53 51 87 30 94 0.69 (0.64–0.74)
Strong AMACR 11 96 25 90 0.53 (0.48–0.59)
Loss of SOX2 25 93 29 92 0.60 (0.55 to 0.65)
The highest degree of abnormality was reported for each endoscopy after examining all biopsies.
AUC= area under the ROC curve, CI= conﬁdence interval, NPV=negative predictive value, PPV=positive predictive value.
van Olphen et al. Medicine (2016) 95:47 www.md-journal.comwas 47%, with a speciﬁcity of 78%. The PPV and NPV were
respectively 20% and 93% (Table 3).
3.3. Cyclin A immunohistochemistry
A positive cyclin A expression was seen in 250/1432 (17%) of the
biopsy series. The interobserver agreement for cyclin A
expression was moderate with a kappa-value of 0.46 (95%
CI: 0.43–0.49). The observers disagreed on cyclin A surface
expression in 278 (19%) biopsy series (Table 4). Cyclin A surface
positivity was seen in 107 (10%) biopsy series without dysplasia,
and was more common in dysplastic BE, including 109 (33%)
biopsy series with LGD, 26 (76%) biopsy series with HGD, and 8
(62%) with EAC (P<0.001). Positive cyclin A surface expression
was more common in biopsy series of cases (32%) than in biopsy
series of controls (14%), and it was associated with an increased
risk of neoplastic progression with a RR of 2.7 (95% CI:
1.9–3.8). This association remained after adjusting for gender,
age, BE length, and esophagitis (adjusted RR of 2.4; 95% CI:
1.7–3.4) and was particularly seen in biopsy series with LGD
(adjusted RR of 5.8; 95% CI: 3.7–9.0) (Table 2). In per-biopsy
analysis, cyclin A had an AUC of 0.59 (95% CI: 0.54–0.64) for
predicting neoplastic progression with a sensitivity of 32%, a
speciﬁcity of 86%, a PPV of 21%, and a NPV of 92% (Table 3).Table 5
Fully adjusted model with histology, cyclin A, p53, AMACR, and
SOX2 immunohistochemistry in biopsy series of cases and
controls.
Variable RR
∗
(95% CI) Change in AUC†3.4. P53, AMACR, and SOX2 immunohistochemistry and
incremental value of cyclin A
The pattern of p53, AMACR, and SOX2 expression were
previously studied and discussed elsewhere.[16–18] Aberrant p53
expression, as well as strong AMACR expression and aberrant
SOX2 expression were more common in biopsy series of cases
than in biopsy series of controls (p53; 51% vs 13%, AMACR;
11% vs 4%, SOX2; 25% vs 7%) and were associated with an
increased risk of neoplastic progression with adjusted RR of 5.6
(95% CI: 4.0–7.8) for aberrant p53 expression, 2.8 (95% CI:
1.6–4.8) for strong AMACR expression, and 4.4 (95% CI:
3.0–6.5) for aberrant SOX2 expression, respectively (Supple-
mentary Table 1, http://links.lww.com/MD/B407) (Table 3). The
highest risk of neoplastic progression was detected in patients
with LGD and concurrent aberrant p53 expression (adjusted RRTable 4
Interobserver agreement for cyclin A expression.
Cyclin A surface positivity <1% ≥1% k value
<1% 958 (67%) 122 (8%) 0.46
≥1% 156 (11%) 196 (14%)
The highest degree of abnormality was reported for each endoscopy after examination of all biopsies.
Cohen k statistics were used to determine interobserver agreement.
5of 9.9; 95% CI: 6.6–14.9) (Supplementary Table 1, http://links.
lww.com/MD/B407). The addition of p53 immunohistochemis-
try improved the AUC compared to the histological diagnosis
alone (from AUC 0.62 to AUC 0.70; 95% CI: 0.66–0.76).
Next, we combined the information on histology, cyclin A,
p53, AMACR, and SOX2 immunohistochemistry in a fully
adjusted model for predicting neoplastic progression in BE
(Table 5). Aberrant p53 expression showed the highest change in
AUC (0.05), to a lesser extent aberrant SOX2 expression (0.014)
and histological diagnosis of LGD (0.005). The biomarkers cyclin
A and AMACR only showed a minimal drop or no drop in AUC
after exclusion (cyclin A: 0.003 and AMACR: 0.0). Importantly,
the addition of SOX2 slightly improved the AUC compared with
the model including only histological diagnosis and p53
immunohistochemistry (from AUC 0.70 to AUC 0.72; 95%
CI: 0.67–0.77) (Fig. 1).4. Discussion
In this large case–control study we evaluated the value of cyclin A
expression for predicting neoplastic progression in patients with
BE. These results were combined with our previously reported
p53, AMACR, and SOX2 immunohistochemical data within the
same cohort using AUC in ROC analysis, to explore the
classiﬁcation performance of different combinations of biomark-
ers. This modeling is a valuable tool for the overall judgment of
the incremental value of the biomarkers studied but not intended
as an exact analytic method.[26] Cyclin A surface positivity
signiﬁcantly increased throughout the metaplasia–dysplasia–-
carcinoma progression steps and was associated with an
increased risk of neoplastic progression. However, the incremen-
tal value of cyclin A expression was limited compared to
histological diagnosis of LGD, p53, and SOX2.
Surveillance of BE patients is under signiﬁcant debate given the
lack of discriminative tools for adequate risk stratiﬁcation.Low-grade dysplasia 1.8 (1.2–2.6) 0.005
Cyclin A positivity 1.4 (1.0–2.1) 0.003
Aberrant p53 3.7 (2.6–5.4) 0.050
Strong AMACR 1.3 (0.8–2.3) 0.000
Loss of SOX2 2.2 (1.4–3.4) 0.014
AUC= area under the curve, BE=Barrett esophagus, CI= conﬁdence interval, RR= relative risk.
∗
RR adjusted for gender, age, BE length and esophagitis and all the other biomarkers.
† Calculated drop of AUC after exclusion of the concerning biomarker compared to AUC of the total
model (AUC of 0.734; 95% CI: 0.687–0.780).
van Olphen et al. Medicine (2016) 95:47 MedicineAdditionally, with the introduction of minimally invasive
endoscopic therapy and the evidence of cancer prevention by
radiofrequency ablation in patients with LGD, there is an
increasing need for accurate dysplasia detection during BE
surveillance.[28,29] Previous studies demonstrated repeatedly the
value of LGD as a risk factor for neoplastic progression, albeit
with a low predictive value due to sampling error and
considerable interobserver variation.[4,6,12–15] Even though the
predictive value of LGD increases with consensus of multiple
pathologists, approximately one-third of the patients with BE are
diagnosed with LGD during surveillance, whereas the 5-year
cumulative incidence of neoplastic progression is only between
5% and 30% in this group.[15,30,31] Although the result of our
study support the use of LGD diagnosed by expert GE
pathologists, as indicator for increased risk of neoplastic
progression, its sensitivity is only 47% and speciﬁcity 78%,
despite using a consensus diagnosis of dysplasia. These results
exemplify the interest in identifying molecular biomarkers to
improve risk stratiﬁcation and eventually cost-effectiveness of BE
surveillance.
In the present study, cyclin A expression was conﬁned to the
base of the crypts in normal columnar gastrointestinal epitheli-
um, as well as inmostNDBE.With increasing grades of dysplasia
the expression of cyclin A progressively shifted toward the
surface epithelium. The percentage of biopsy series with a
positive cyclin A surface expression increased from 10% in
NDBE to 62% in biopsy series with EAC, which corresponds to
previous studies.[20,21] A recent study identiﬁed cyclin A
expression as 1 of a 3-biomarker panel which provides a more
accurate and objective diagnosis of dysplasia in BE.[20] Our
results conﬁrmed the correlation between dysplasia and cyclin A
expression and hence potential as diagnostic tool for dysplasia
detection.
Positive cyclin A surface expression was detected more
frequently in cases than in controls, and was signiﬁcantly
associated with an increased risk of developing HGD or EAC
(adjusted RR of 2.4; 95% CI: 1.7–3.4), particularly in dysplastic
BE. The results of previous studies evaluating the value of cyclin
A expression for predicting neoplastic progression are conﬂicting.
A small case–control study showed that cyclin A surface
expression was signiﬁcantly associated with an increased risk
of neoplastic progression (OR 7.6; 95%CI: 1.6–37.0), whereas a
more recent larger population-based study could not conﬁrm this
correlation and only found a trend toward an increased risk of
progression, which eventually lost signiﬁcance in a multivariate
analysis (OR 1.32; 95% CI: 0.66–2.66).[19,21] These conﬂicting
results might be explained by a rather challenging interpretation
of cyclin A immunohistochemistry. We found a moderate
interobserver agreement with a kappa value of 0.46. This is
low compared to the interobserver agreement of the other
biomarkers p53 and SOX2 (kappa values between 0.70 and
0.86).[17,18,32]
The biomarker with the greatest body of evidence remains
aberrant p53 expression (adjusted RR in fully adjusted model of
3.7 (95%CI: 2.6–5.4), change in AUC 0.05) and to a lesser extent
aberrant SOX2 expression (change in AUC 0.014). Cyclin A
positivity showed only a minimal drop in AUC after exclusion
(0.003). These ﬁndings might have important and clinically
relevant implications. Assessment of p53 and SOX2 are
promising to select high-risk patients for either intensiﬁed
surveillance or ablation therapy and may eventually contribute
to a more cost-effective management. Although routine p53 and
SOX2 staining and assessment incur higher costs than histology6alone, application of this panel of biomarkers has the potential to
reduce the overall costs related of Barrett surveillance. Patients at
low-risk of neoplastic progression, that is, the majority of the
patients with LGD, might be followed-up less intensively with the
potential to eventually discharge them. However, a more detailed
cost-effectiveness analysis should be performed to evaluate the
economic value of p53 and SOX2 immunohistochemistry, which
is beyond the scope of this study.
Our study has several strengths. The large cohort of BE
patients was prospectively followed-up according to a stringent
scheme during a long follow-up time, clinical, endoscopic, and
pathological data were collected. Additionally, a standardized
endoscopy and biopsy protocol was used. All stained slides were
assessed by at least 2 experienced observers blinded for clinical
outcome and in case of disagreement an expert pathologist
reviewed the slides for ﬁnal diagnosis. Another major strength of
this study was that we tested multiple biomarkers in the same
cohort of BE patients so we could identify the smallest panel of
biomarkers with the highest predictive value for neoplastic
progression, and which can be performed on routine clinical
collected FFPE tissue.
Our study also has some limitations. Although immunohis-
tochemistry is an established clinical examination method and
easily applicable to standard clinical pathological laboratories,
the scoring of the expression is a subjective assessment. It will
require standardization of processing and scoring for reliable
routine clinical application. In spite of this, our previous studies
have shown good interobserver agreement for both p53 and
SOX2 and they were relatively simple and straightforward to
interpret.[17,18] Further validation of this panel of biomarkers in
large prospective studies is required to conﬁrm our ﬁndings.
Secondly, as all patients with BE, the patients considered as
controls in this study still have the potential to progress to HGD
or EAC during the future follow-up. However, since their median
follow-up time was 6.5 years (which is more the twice the follow-
up time of the cases), and the incidence of progression in only 2.6/
1000 patients per year, the chance of progression in the controls
is slim.[6]
In conclusion, cyclin A surface expression was associated with
an increased risk of neoplastic progression in BE patients, but its
ability to predict neoplastic progression is limited compared to
the biomarkers p53 and SOX2. The use of biomarkers has the
potential to signiﬁcantly improve risk stratiﬁcation in Barrett
surveillance and hence the cost-effectiveness of Barrett surveil-
lance programs.
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